In vitro and in vivo efficacy of anti-chikungunya virus monoclonal antibodies produced in wild-type and glycoengineered Nicotiana benthamiana plants

Plant Biotechnology Journal

Volumn 18, Issue 1, 2020, Pages 266-273

  Hurtado, Jonathan ^a   Acharya, Dhiraj ^b   Lai, Huafang ^a   Sun, Haiyan ^a   Kallolimath, Somanath ^c   Steinkellner, Herta ^c   Bai, Fengwei ^b   Chen, Qiang ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN MISSISSIPPI   (United States)

^c UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

chikungunya virus; glycoengineering; glycosylation; monoclonal antibody; neutralization; plant made antibody; plant made therapeutics

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ANIMAL; BIOSYNTHESIS; CHIKUNGUNYA; CHIKUNGUNYA VIRUS; METABOLISM; MOUSE; TOBACCO; TRANSGENIC PLANT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; MICE; PLANTS, GENETICALLY MODIFIED; TOBACCO;

EID: 85068189460     PISSN: 14677644     EISSN: 14677652     Source Type: Journal    
DOI: 10.1111/pbi.13194     Document Type: Article

References (51)

1. Acharya, D., Paul, A.M., Anderson, J.F., Huang, F. and Bai, F. (2015) Loss of glycosaminoglycan receptor binding after mosquito cell passage reduces chikungunya virus infectivity. PLoS Negl. Trop Dis. 9, e0004139.
2. Arntzen, C. (2015) Plant-made pharmaceuticals: from ‘Edible Vaccines’ to Ebola therapeutics. Plant Biotechnol. J. 13, 1013–1016.
3. Bendandi, M., Marillonnet, S., Kandzia, R., Thieme, F., Nickstadt, A., Herz, S., Frode, R. et al. (2010) Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma. Ann. Oncol. 21, 2420–2427.
4. Broeckel, R., Fox, J.M., Haese, N., Kreklywich, C.N., Sukulpovi-Petty, S., Legasse, A., Smith, P.P. et al. (2017) Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques. PLoS Negl. Trop Dis. 11, e0005637.
5. Cardona-Ospina, J.A., Sepulveda-Arias, J.C., Mancilla, L. and Gutierrez-Lopez, L.G. (2016) Plant expression systems, a budding way to confront chikungunya and Zika in developing countries? F1000Res, 5, 2121.
6. Chen, Q. (2016) Glycoengineering of plants yields glycoproteins with polysialylation and other defined N-glycoforms. Proc. Natl Acad. Sci. 113, 9404–9406.
7. Chen, Q. and Davis, K. (2016) The potential of plants as a system for the development and production of human biologics. F1000Res, 5, pii: F1000.
8. Chen, Q. and Lai, H. (2014a) Gene delivery into plant cells for recombinant protein production. Biomed. Res. Int. 2014, 10.
9. Chen, Q. and Lai, H. (2014b) Plant-derived monoclonal antibodies as human biologics for infectious disease and cancer. In Plant-derived Pharmaceuticals: Principles and Applications for Developing Countries(Hefferon, K.L., ed), pp. 42–75. Croydon, UK: CABI.
10. Chen, Q., Lai, H., Hurtado, J., Stahnke, J., Leuzinger, K. and Dent, M. (2013) Agroinfiltration as an effective and scalable strategy of gene delivery for production of pharmaceutical proteins. Adv. Technol. Biol. Med. 1, 103–112.
11. De Muynck, B., Navarre, C. and Boutry, M. (2010) Production of antibodies in plants: status after twenty years. Plant Biotechnol. J. 8, 529–563.
12. Dent, M., Hurtado, J., Paul, A.M., Sun, H., Lai, H., Yang, M., Esqueda, A. et al. (2016) Plant-produced anti-dengue virus monoclonal antibodies exhibit reduced antibody-dependent enhancement of infection activity. J. Gen. Virol. 97, 3280–3290.
13. Forthal, D.N., Gach, J.S., Landucci, G., Jez, J., Strasser, R., Kunert, R. and Steinkellner, H.(2010) Fc-Glycosylation Influences Fcγ Receptor Binding and Cell-Mediated Anti-HIV Activity of Monoclonal Antibody 2G12. The Journal of Immunology. 185, 6876–6882.
14. Garber, K.(2018) No added sugar: antibody makers find an upside to 'no fucose'. Nature Biotechnology 36, 1025–1027.
15. Giritch, A., Marillonnet, S., Engler, C., van Eldik, G., Botterman, J., Klimyuk, V. and Gleba, Y. (2006) Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proc. Natl. Acad. Sci. USA, 103, 14701–14706.
16. He, J., Lai, H., Brock, C. and Chen, Q. (2012) A novel system for rapid and cost-effective production of detection and diagnostic reagents of west Nile virus in plants. J. Biomed. Biotechnol. 2012, 1–10.
17. He, J., Lai, H., Engle, M., Gorlatov, S., Gruber, C., Steinkellner, H., Diamond, M.S. et al. (2014) Generation and analysis of novel plant-derived antibody-based therapeutic molecules against west nile virus. PLoS ONE, 9, e93541.
18. Hiatt, A., Bohorova, N., Bohorov, O., Goodman, C., Kim, D., Pauly, M.H., Velasco, J. et al. (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl Acad. Sci. 111, 5992–5997.
19. Holtz, B.R., Berquist, B.R., Bennett, L.D., Kommineni, V.J.M., Munigunti, R.K., White, E.L., Wilkerson, D.C. et al. (2015) Commercial-scale biotherapeutics manufacturing facility for plant-made pharmaceuticals. Plant Biotechnol. J. 13, 1180–1190.
20. Jefferis, R. (2005) Glycosylation of recombinant antibody therapeutics. Biotechnol. Prog. 21, 11–16.
21. Jefferis, R. (2012) Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159–166.
22. Kam, Y.W., Simarmata, D., Chow, A., Her, Z., Teng, T.S., Ong, E.K., Renia, L. et al. (2012) Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protection. J. Infect. Dis. 205, 1147–1154.
23. Kam, Y.-W., Pok, K.-Y., Eng, K.E., Tan, L.-K., Kaur, S., Lee, W.W.L., Leo, Y.-S. et al. (2015) Sero-prevalence and cross-reactivity of chikungunya virus specific anti-E2EP3 antibodies in arbovirus-infected patients. PLoS Negl. Trop Dis. 9, e3445.
24. Lai, H. and Chen, Q. (2012) Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current Good Manufacture Practice regulations. Plant Cell Rep. 31, 573–584.
25. Lai, H., Engle, M., Fuchs, A., Keller, T., Johnson, S., Gorlatov, S., Diamond, M.S. et al. (2010) Monoclonal antibody produced in plants efficiently treats West Nile virus infection in mice. Proc. Natl. Acad. Sci. USA, 107, 2419–2424.
26. Lai, H., He, J., Engle, M., Diamond, M.S. and Chen, Q. (2012) Robust production of virus-like particles and monoclonal antibodies with geminiviral replicon vectors in lettuce. Plant Biotechnol. J. 10, 95–104.
27. Lai, H., He, J., Hurtado, J., Stahnke, J., Fuchs, A., Mehlhop, E., Gorlatov, S. et al. (2014) Structural and functional characterization of an anti-West Nile virus monoclonal antibody and its single-chain variant produced in glycoengineered plants. Plant Biotechnol. J. 12, 1098–1107.
28. Lai, H., Paul, A.M., Sun, H., He, J., Yang, M., Bai, F. and Chen, Q. (2018) A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity. Vaccine, 36, 1846–1852.
29. Leuzinger, K., Dent, M., Hurtado, J., Stahnke, J., Lai, H., Zhou, X. and Chen, Q. (2013) Efficient agroinfiltration of plants for high-level transient expression of recombinant proteins. J. Vis. Exp. 77, e50521. https://doi.org/10.3791/50521
30. Lomonossoff, G.P. and D'Aoust, M.-A. (2016) Plant-produced biopharmaceuticals: A case of technical developments driving clinical deployment. Science, 353, 1237–1240.
31. Ma, J.K.C., Drossard, J., Lewis, D., Altmann, F., Boyle, J., Christou, P., Cole, T. et al. (2015) Regulatory approval and a first-in-human phase I clinical trial of a monoclonal antibody produced in transgenic tobacco plants. Plant Biotechnol. J. 13, 1106–1120.
32. Moldt, B., Shibata-Koyama, M., Rakasz, E.G., Schultz, N., Kanda, Y., Dunlop, D.C., Finstad, S.L. et al. (2012) A Nonfucosylated Variant of the anti-HIV-1 Monoclonal antibody b12 Has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86, 6189–6196.
33. Montero-Morales, L. and Steinkellner, H. (2018) Advanced plant-based glycan engineering. Front. Bioeng. Biotechnol. 6, 81.
34. Pal, P., Dowd, K.A., Brien, J.D., Edeling, M.A., Gorlatov, S., Johnson, S., Lee, I. et al. (2013) Development of a highly protective combination monoclonal antibody therapy against chikungunya virus. PLoS Pathog. 9, e1003312.
35. Prevail, II Writing Group. (2016) A randomized, controlled trial of ZMapp for ebola virus infection. N. Engl. J. Med. 375, 1448–1456.
36. Reichert, J.M. (2012) Marketing approval of mogamulizumab AU – Beck, Alain. mAbs, 4, 419–425.
37. Salazar-Gonzalez, J.A., Angulo, C. and Rosales-Mendoza, S. (2015) Chikungunya virus vaccines: Current strategies and prospects for developing plant-made vaccines. Vaccine, 33, 3650–3658.
38. Schilte, C., Staikowsky, F., Couderc, T., Madec, Y., Carpentier, F., Kassab, S., Albert, M.L. et al. (2013) Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal study. PLoS Negl. Trop Dis. 7, e2137.
39. Shevitz, J., Bonham-Carter, J., Lim, J. and Sinclair, A. (2011) An economic comparison of three cell culture techniques. BioPharm. Int. 24, 1–4.
40. Smith, Scott A., Silva, Laurie A., Fox, Julie M., Flyak, A.I., Kose, N., Sapparapu, G., Khomandiak, S. et al. (2015) Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell. Host. Microbe. 18, 86–95.
41. Strasser, R., Altmann, F. and Steinkellner, H. (2014) Controlled glycosylation of plant-produced recombinant proteins. Curr. Opin. Biotechnol. 30, 95–100.
42. Sun, H., Chen, Q. and Lai, H. (2018) Development of antibody therapeutics against flaviviruses. Int. J. Mol. Sci. 19, 54.
43. Tuse, D., Tu, T. and McDonald, K. (2014) Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes. Biomed. Res. Int. 2014, 10.
44. Voss, J.E., Vaney, M.-C., Duquerroy, S., Vonrhein, C., Girard-Blanc, C., Crublet, E., Thompson, A. et al. (2010) Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature, 468, 709.
45. Weaver, S.C. and Forrester, N.L. (2015) Chikungunya: evolutionary history and recent epidemic spread. Antiviral Res. 120, 32–39.
46. Yang, M., Dent, M., Lai, H., Sun, H. and Chen, Q. (2017a) Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus. Vaccine, 35, 4287–4294.
47. Yang, M., Lai, H., Sun, H. and Chen, Q. (2017b) Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice. Sci. Rep. 7, 7679.
48. Yang, M., Sun, H., Lai, H., Hurtado, J. and Chen, Q. (2018) Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice. Plant Biotechnol. J. 16, 572–580.
49. Yoon, I.K., Alera, M.T., Lago, C.B., Tac-An, I.A., Villa, D., Fernandez, S., Thaisomboonsuk, B. et al. (2015) High rate of subclinical chikungunya virus infection and association of neutralizing antibody with protection in a prospective cohort in the Philippines. PLoS Negl. Trop Dis. 9, e0003764.
50. Zeitlin, L. and Haydon, H. (2015) Design and testing of ZMapp and manufacturing challenges. Soc. Mol. Farm. 1–37.
51. Zeitlin, L., Pettitt, J., Scully, C., Bohorova, N., Kim, D., Pauly, M., Hiatt, A. et al. (2011) Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl. Acad. Sci. USA, 108, 20690–20694.